Supreme Court Allows Mifepristone to Remain Available by Mail Nationwide
The U.S. Supreme Court has ruled that the abortion pill mifepristone can continue to be distributed by mail across the nation without requiring an in-person consultation with a clinician. This decision grants emergency requests filed by drug manufacturers Danco Laboratories and GenBioPro, effectively blocking a recent ruling by the 5th U.S. Circuit Court of Appeals that had threatened to restrict access to the medication. The 5th Circuit's May 1 decision, which favored the state of Louisiana, argued against the current distribution methods. However, the Supreme Court's intervention ensures no disruption to the drug's availability while legal proceedings continue. Justices Clarence Thomas and Samuel Alito issued dissenting opinions. Justice Thomas characterized the mailing of mifepristone as illegal in Louisiana and criticized the manufacturers, while Justice Alito questioned the Biden administration's 2023 decision to allow mail-order access. Mifepristone, used in conjunction with another drug, represents the most common method of abortion in the United States. This ruling marks a significant development in the ongoing legal battles surrounding reproductive rights and FDA regulations post-Roe v. Wade.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection